Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Preferred Stock Liabilities: 2019-2020

Historic Preferred Stock Liabilities for Keros Therapeutics (KROS) over the last 1 years, with Mar 2020 value amounting to $75.7 million.

  • Keros Therapeutics' Preferred Stock Liabilities rose 665.56% to $75.7 million in Q1 2020 from the same period last year, while for Mar 2020 it was $75.7 million, marking a year-over-year increase of 665.56%. This contributed to the annual value of $19.9 million for FY2019, which is N/A change from last year.
  • As of Q1 2020, Keros Therapeutics' Preferred Stock Liabilities stood at $75.7 million, which was up 279.73% from $19.9 million recorded in Q4 2019.
  • In the past 5 years, Keros Therapeutics' Preferred Stock Liabilities registered a high of $75.7 million during Q1 2020, and its lowest value of $9.9 million during Q1 2019.
  • For the 2-year period, Keros Therapeutics' Preferred Stock Liabilities averaged around $25.1 million, with its median value being $9.9 million (2019).
  • Data for Keros Therapeutics' Preferred Stock Liabilities shows a peak YoY soared of 665.56% (in 2020) over the last 5 years.
  • Keros Therapeutics' Preferred Stock Liabilities (Quarterly) stood at $19.9 million in 2019, then soared by 665.56% to $75.7 million in 2020.
  • Its last three reported values are $75.7 million in Q1 2020, $19.9 million for Q4 2019, and $9.9 million during Q3 2019.